

**Remarks**

Following this amendment, Claims 15, 16, 18, 20 and 23 are pending. Claims 1-14, 17, 19, 21, 22, 24 and 25 are cancelled.

Claim 15 has been amended to include Examples 6 and 11-16 within its scope. In addition, the name of one compound (Example 7) has been corrected. The error is apparent and the correct name also apparent from the structure of the compound as shown.

Claims 16, 23 and claim 20 (in part) have been amended to reflect proper dependency. Claim 20 has also been amended to limit the claimed use to treating obesity.

Applicants respectfully contend none of the amendments add new matter.

Applicants request favorable consideration of this invention as presently claimed.

Respectfully submitted,



John C. Demeter  
Attorney for Applicants  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

April 11, 2006